Spiriva FDA Approval History
FDA Approved: Yes (First approved January 30, 2004)
Brand name: Spiriva
Generic name: tiotropium bromide
Dosage form: Inhalation Powder
Company: Boehringer Ingelheim
Treatment for: COPD, Maintenance
Spiriva HandiHaler (tiotropium bromide) is an anticholinergic indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), and for reducing COPD exacerbations.
Development timeline for Spiriva
| Date | Article |
|---|---|
| Dec 18, 2009 | Approval FDA Approves Spiriva HandiHaler for the Reduction of COPD Exacerbations |
| Jan 30, 2004 | Approval Spiriva HandiHaler Boehringer Ingelheim - Treatment for Chronic Obstructive Pulmonary Disease (COPD) |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.